Patients with diabetic nephropathy have a poor renal and cardiovascular prognosis. Patients are often treated with renin-angiotensin-aldosterone (RAAS) blockade, but hyperkalemia is a frequent challenge to this treatment, leading to suboptimal dosing or discontinuation. Epidemiological studies have indicated, that hyperkalemia might impair the renoprotective effects of RAAS blockade.
Lokelma is a new type of medication for the treatment of hyperkalemia. It is ingested orally and captures potassium in the intestine.
In this study, we want to examine if adjunctive treatment with Lokelma once daily for 12 weeks can improve the effects of standard RAAS blockade, as measured by urine albumin creatinine ration (UACR) in patients with diabetes, hyperkalemia and makroalbuminuria.
The future potential of this combination could be to keep more individuals on optimal dosing of RAAS blockade and thereby potentially improve the overall outcome in this high-risk population.
Department of Medicine, University Hospital Zealand, Roskilde
Department of Nephrology, University Hospital Uppsala, Sweden
Department of Nephrology, University Hospital Linköping, Sweden
Department of Medicine, Örebro University Hospital, Sweden